Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
NCT ID: NCT06635980
Last Updated: 2025-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2025-05-14
2034-10-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy
NCT05665920
Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy
NCT02212860
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT05528133
Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer
NCT05850637
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
NCT02515110
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Compare the rate of grade (G)3 or higher radiation treatment related adverse events with the use of preoperative and postoperative radiation within the first 2-years for groups A-D.
CORRELATIVE AND EXPLORATORY OBJECTIVES:
I. Grade 3 wound complications and seroma infection between preop and postoperative radiation.
II. Locoregional control with or without surgery at 2-years in group D (Her2+). III. To evaluate radiographic complete response and near complete response. IV. To estimate the 5-year locoregional control, distant recurrence, invasive disease-free survival, cause-specific survival, and overall survival.
V. To evaluate patient-reported outcomes. VI. To evaluate clinical features, treatment technique, dose-volume parameters, histologic and genetic variants associated with adverse events, and fair and poor cosmetic outcomes or unplanned surgical intervention.
VII. Evaluate tumor mutation signatures before and after chemotherapy, radiation, and surgery, correlate tumor mutation signatures before and after radiation with pathologic information at the time of surgery.
VIII. To describe the pathologic changes seen in breast cancer patients with preoperative radiation.
IX. Evaluate circulating tumor deoxyribonucleic acid (DNA), tumor infiltrating lymphocytes, neo-epitopes, and peripheral blood mononuclear before and after chemotherapy, radiation, and surgery; correlate tumor mutation signatures before and after radiation with pathologic information at the time of surgery.
X. Group A-D: Determine the rate of implant/tissue expander failure after preop and postop radiation.
XI. Group A-C: To determine the pathologic complete response (pCR) rate and near pathologic rate with cellularity \<10% after neoadjuvant chemotherapy and hypofractionated radiotherapy to the whole breast with nodal irradiation if indicated, based on the postsurgical specimen.
XII. Group D: Determine locoregional control with the use of preoperative radiation conformal radiation. It will be determined based on the number of patients with controlled locoregional disease at 6-months.
XIII. Group A-C: To determine true radiographic complete response based on post treatment positron emission tomography (PET) standardized uptake value (SUV) \<2.5 or uptake \< mediastinum.
XIV. Group A-C: To determine the pathologic complete response (pCR) rate and near pathologic rate with cellularity \<10% after neoadjuvant chemotherapy and hypofractionated radiotherapy to the whole breast with nodal irradiation if indicated, based on the postsurgical specimen.
XV. Group E: To determine the rates of surgery for locoregional disease after RT at 2 and 5-years.
XVI. Group E: To determine the rates of persistent disease in the breast or regional lymphatics after RT at 2 and 5-years.
OUTLINE: Patients with low risk and high risk estrogen receptor (ER) positive disease, triple negative disease and HER2 positive disease without complete response are randomized to 1 of 2 arms. Patients with HER2 positive, complete response disease are assigned to arm I.
ARM I: Patients undergo standard of care (SOC) chemotherapy followed by breast hypofractionated radiotherapy once daily (QD) for a total of 5 fractions. Patients then undergo SOC breast surgery 10 weeks after radiation treatment. Patients also undergo computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), contrast-enhanced digital mammography (CEDM), and/or breast ultrasound (US) throughout the study. Additionally, patients undergo a biopsy and may undergo optional blood sample collection and tissue collection on study.
ARM II: Patients undergo SOC chemotherapy and SOC breast surgery followed by breast hypofractionated radiotherapy QD for a total of 5 fractions. Patients also undergo CT, MRI, PET, CEDM, and/or breast US throughout the study. Additionally, patients undergo a biopsy and may undergo optional blood sample collection and tissue collection on study.
After completion of study treatment, patients are followed up at 16 weeks, 6 months, 12 months, 24 months, 36 months, 48 months and at 5 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (Preoperative radiation therapy + surgery)
Patients undergo SOC chemotherapy followed by breast hypofractionated radiotherapy QD for a total of 5 fractions. Patients then undergo SOC breast surgery 10 weeks after radiation treatment. Patients also undergo CT, MRI, PET, CEDM, and/or breast US throughout the study. Additionally, patients undergo a breast biopsy and may undergo optional blood sample collection and tissue collection on study.
Biopsy of Breast
Undergo breast biopsy
Biospecimen Collection
Undergo blood sample collection
Breast Surgery
Undergo breast surgery
Chemotherapy
Receive SOC chemotherapy
Computed Tomography
Undergo CT
Contrast Enhanced Digital Mammography
Undergo CEDM
Hypofractionated Radiation Therapy
Undergo hypofractionated radiotherapy
Magnetic Resonance Imaging
Undergo MRI
Positron Emission Tomography
Undergo PET
Survey Administration
Ancillary studies
Tissue Collection
Undergo tissue collection
Ultrasound Imaging
Undergo ultrasound
Arm II (Surgery + postoperative radiation therapy)
Patients undergo SOC chemotherapy and SOC breast surgery followed by breast hypofractionated radiotherapy QD for a total of 5 fractions. Patients also undergo CT, MRI, PET, CEDM, and/or breast US throughout the study. Additionally, patients undergo a breast biopsy and may undergo optional blood sample collection and tissue collection on study.
Biopsy of Breast
Undergo breast biopsy
Biospecimen Collection
Undergo blood sample collection
Breast Surgery
Undergo breast surgery
Chemotherapy
Receive SOC chemotherapy
Computed Tomography
Undergo CT
Contrast Enhanced Digital Mammography
Undergo CEDM
Hypofractionated Radiation Therapy
Undergo hypofractionated radiotherapy
Magnetic Resonance Imaging
Undergo MRI
Positron Emission Tomography
Undergo PET
Survey Administration
Ancillary studies
Tissue Collection
Undergo tissue collection
Ultrasound Imaging
Undergo ultrasound
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biopsy of Breast
Undergo breast biopsy
Biospecimen Collection
Undergo blood sample collection
Breast Surgery
Undergo breast surgery
Chemotherapy
Receive SOC chemotherapy
Computed Tomography
Undergo CT
Contrast Enhanced Digital Mammography
Undergo CEDM
Hypofractionated Radiation Therapy
Undergo hypofractionated radiotherapy
Magnetic Resonance Imaging
Undergo MRI
Positron Emission Tomography
Undergo PET
Survey Administration
Ancillary studies
Tissue Collection
Undergo tissue collection
Ultrasound Imaging
Undergo ultrasound
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histological confirmation of breast cancer
* Clinical stage T1-T4 N0-3 M0
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2
* Able to and provides Institutional Review Board (IRB)-approved study specific written informed consent
* Able to complete all mandatory tests listed in the trial
* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
* Indications for radiotherapy for breast cancer
Exclusion Criteria
* Severe active co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or providing informed consent in the judgment of the principal investigator
* Active systemic lupus or scleroderma
* Pregnancy
* Women of childbearing potential who are unwilling to employ adequate contraception
* Prior receipt of ipsilateral breast or chest wall radiation
* Recurrent breast cancer
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carlos E. Vargas, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2024-08356
Identifier Type: REGISTRY
Identifier Source: secondary_id
22-009070
Identifier Type: OTHER
Identifier Source: secondary_id
GMROA2234
Identifier Type: OTHER
Identifier Source: secondary_id
GMROA2234
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.